[1]徐瑞颜,成金燕,李乐愚.复方番石榴合剂治疗超重肥胖型2型糖尿病疗效及对患者肠黏膜屏障功能的影响[J].陕西中医,2022,(8):1045-1048.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.013]
　XU Ruiyan,CHENG Jinyan,LI Leyu.Effects of compound Fanshiliu mixture on clinical efficacy and intestinal mucosal barrier function in patients with overweight-obesity complicated with type 2 diabetes mellitus[J].,2022,(8):1045-1048.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.013]
点击复制

复方番石榴合剂治疗超重肥胖型2型糖尿病疗效及对患者肠黏膜屏障功能的影响

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2022年8期
页码:
1045-1048
栏目:
临床研究
出版日期:
2022-08-05

文章信息/Info

Title:
Effects of compound Fanshiliu mixture on clinical efficacy and intestinal mucosal barrier function in patients with overweight-obesity complicated with type 2 diabetes mellitus
作者:
徐瑞颜; 成金燕; 李乐愚
(广州中医药大学附属中山市中医院内分泌代谢科,广东 中山 528400)
Author(s):
XU Ruiyan; CHENG Jinyan; LI Leyu
(Department of Endocrinology and Metabolism,Zhongshan Hospital of Traditional Chinese Medicine,Affiliated to Guangzhou University of Chinese Medicine,Zhongshan 528400,China)
关键词:
2型糖尿病;  超重肥胖;  复方番石榴合剂;  肠黏膜屏障功能;  二胺氧化酶;  脂多糖;  D-乳酸
Keywords:
Type 2 diabetes mellitus;  Overweight-obesity;  Compound Fanshiliu mixture;  Intestinal mucosal barrier function;  Diamine oxidase;  Lipopolysaccharide;  D-lactic acid
分类号:
R 587.1
DOI:
DOI:10.3969/j.issn.1000-7369.2022.08.013
文献标志码:
A
摘要:
目的:探究复方番石榴合剂对超重肥胖型2型糖尿病患者中医临床疗效及肠黏膜屏障功能的影响。方法:选取100例脾虚胃热证超重肥胖型2型糖尿病患者为研究对象,遵循随机分组的原则,分为观察组和对照组,各50例。对照组予二甲双胍肠溶片和/或胰岛素基础治疗,观察组在对照组的基础上使用复方番石榴制剂联合治疗。比较两组患者治疗后临床疗效差异,评估两组患者治疗前后中医证候积分(心下痞满、胀闷呕恶、呃逆、水谷不消、纳呆、便溏)、肠黏膜屏障功能[二胺氧化酶(DAO)、脂多糖(LPS)、D-乳酸(DLC)]变化,分析两组患者治疗期间药物不良反应差异。结果:治疗12周后,观察组患者总有效率高于对照组(P<0.05); 治疗12周后,两组患者中医证候积分及DAO、LPS、DLC等肠黏膜屏障功能指标均较治疗前下降,且观察组低于同期对照组(P<0.05); 治疗期间,两组患者腹胀腹泻、胃部不适、恶心呕吐发生率及总发生率比较,差异无统计学意义(P>0.05)。结论:复方番石榴合剂治疗超重肥胖型2型糖尿病患者可有效减轻患者中医症状,且能调节肠黏膜屏障功能。
Abstract:
Objective:To explore the effects of compound Fanshiliu mixture on TCM clinical efficacy and intestinal mucosal barrier function in patients with overweight-obesity complicated with type 2 diabetes mellitus.Methods:100 patients with overweight-obesity complicated with type 2 diabetes mellitus of spleen deficiency and stomach heat syndrome were selected as the research subjects,and they were divided into the observation group(n=50)and the control group(n=50)by following the principle of random grouping.The control group was given metformin enteric-coated tablets and/or insulin basal therapy,while the observation group was combined with compound Fanshiliu mixture on the basis of the control group.The clinical efficacy of the two groups of patients was compared after treatment,and the changes in scores of TCM syndromes(epigastric fullness,distension and nausea,hiccup,indigestion of essence of water and grain,anorexia,loose stool)and intestinal mucosal barrier function [diamine oxidase(DAO),lipopolysaccharide(LPS),D-lactic acid(DLC)] were evaluated in the two groups before and after treatment.The differences in adverse drug reactions were analyzed in the two groups of patients during treatment.Results:After 12 weeks of treatment,the total effective rate in the observation group was higher than that in the control group(P<0.05).After 12 weeks of treatment,the scores of TCM syndromes and levels of intestinal mucosal barrier function indicators of DAO,LPS and DLC in the two groups were reduced compared with those before treatment,and the scores and levels in the observation group were lower compared with those in the control group(P<0.05).Within 12 weeks of treatment,there were no statistical differences in the incidence rates of abdominal distension and diarrhea,stomach discomfort and nausea and vomiting and total incidence rate between the two groups of patients(P>0.05).Conclusion:Compound Fanshiliu mixture in the treatment of patients with overweight-obesity complicated with type 2 diabetes mellitus can effectively relieve the TCM symptoms,and it can regulate the intestinal mucosal barrier function.

参考文献/References:

[1] 李晓玲,巩秋红,安雅莉,等.胰高糖素样肽-1受体激动剂可降低超重/肥胖的2型糖尿病合并冠心病患者的再发心血管风险[J].中华糖尿病杂志,2019,11(5):341-346.
[2] 闫 妮,刘玲娇,余湘尤,等.中性粒细胞与淋巴细胞比值在2型糖尿病合并糖尿病肾病患者中的变化及检测价值研究[J].陕西医学杂志,2021,50(6):673-677.
[3] 魏秀秀,苟筱雯,赵林华,等.态靶辨证在肝胃郁热型肥胖2型糖尿病中的运用——大柴胡汤加黄连、知母、赤芍[J].辽宁中医杂志,2020,47(3):1-3.
[4] 冯 颖,苏衍进,司海龙,等.水陆地黄汤联合盐酸贝那普利对气阴两虚夹瘀型糖尿病肾病氧化应激及临床指标的影响[J].陕西中医,2020,41(5):605-608.
[5] 陈娇月,山秀杰,刘 敏,等.骨化三醇联合二甲双胍对腹型肥胖2型糖尿病早期肾病的影响[J].河北医学,2020,26(4):602-605.
[6] 孙家燕,张晓妍.磷酸西格列汀、二甲双胍及阿卡波糖联合应用治疗2型糖尿病伴骨质疏松疗效及对患者糖脂代谢、骨代谢水平的影响[J].陕西医学杂志,2021,50(10):1275-1278.
[7] 刘爱霞,刘鲁豫,田红香.新诊断2型糖尿病患者骨钙素与胰岛素抵抗、胰岛β细胞功能及血脂的相关性研究[J].解放军预防医学杂志,2018,36(3):347-349,356.
[8] 梁晓春,林 兰.《糖尿病中西医结合诊疗规范(2010)》关键内容解读[J].中华全科医师杂志,2012,11(1):24-25.
[9] 翁建平.基层糖尿病规范化诊疗手册[M].北京:人民军医出版社,2014:118-119.
[10] 赵玉静,李建宽,张 鑫,等.番石榴叶黄酮类化学成分及其抗氧化活性研究[J].中国中药杂志,2018,43(4):760-765.
[11] 代 培,许光远,刘铜华,等.番石榴叶提取物调节白色脂肪组织棕色化作用机制研究[J].陕西中医,2021,42(3):275-278.
[12] 黄溥玮,卢健棋,林 浩,等.中药五指毛桃的化学成分、药理作用及临床应用研究进展[J].辽宁中医药大学学报,2020,22(12):93-96.
[13] 张祺嘉钰,赵佩媛,孙 静,等.山楂的化学成分及药理作用研究进展[J].西北药学杂志,2021,36(3):521-523.
[14] 黎运呈,王 艳,王秋景,等.山楂叶总黄酮对非酒精性脂肪性肝病细胞病理及血脂影响的实验研究[J].中西医结合肝病杂志,2018,28(2):108-110,117.
[15] 赵进喜,王世东,黄为钧,等.从证候、体质、病证的关系探讨糖尿病肠道菌群的相关研究[J].北京中医药,2018,37(11):1010-1013.
[16] 王 洁,茹 睿,孙 军,等.肠内营养联合益生菌对急性缺血性脑卒中患者神经介入治疗后营养状态的影响[J].成都医学院学报,2021,16(1):29-32.
[17] 杨 娟,马 莉,郭亚楠,等.lncRNA NKILA靶向miR-1236-3p对脂多糖诱导的支气管上皮细胞损伤的影响[J].第三军医大学学报,2020,42(16):1648-1654.
[18] 陈 颖.妊娠糖尿病患者血清脂多糖、蛋白质核因子-κB、可溶性细胞间黏附分子-1、脂联素水平变化及意义[J].中国临床医生杂志,2016,44(5):88-90.
[19] 林玉玲,刘 琳,籍胤玺,等.2型糖尿病合并牙周炎患者龈沟液中炎症因子、瘦素和脂多糖水平的变化及其临床意义[J].中国糖尿病杂志,2016,24(9):815-819.
[20] 龙厚东,陈晓旦,郭善禹,等.血清D-乳酸、HDC、PCT联合检测对腹部手术患者肠道屏障受损的预测价值[J].国际检验医学杂志,2021,42(9):1037-1041,1045.
[21] 丁春龙,王玉海,杨理坤,等.血清D-乳酸、细菌内毒素及二胺氧化酶在创伤性颅脑损伤后肠道黏膜屏障功能评估中的作用[J].中华神经外科杂志,2019,35(12):1258-1261.
[22] 闫丽华,帅 飞.化浊清解方联合柳氮磺吡啶对溃疡性结肠炎患者肠黏膜屏障功能、血清炎症因子及其机制研究[J].药物生物技术,2020,27(4):319-323.
[23] 谢梦秋,林洁玉,谢少燕,等.复方番石榴制剂治疗妊娠期糖尿病效果研究[J].山西医药杂志,2021,50(13):2101-2102.
[24] 张 俏,罗 影,刘学政.番石榴叶总三萜改善糖尿病大鼠视网膜损伤的作用机制研究[J].天津医药,2020,48(12):1165-1168.
[25] 林洁玉,谢梦秋,谢少燕,等.复方番石榴制剂对超重肥胖2型糖尿病患者胰岛素抵抗影响的临床研究[J].罕少疾病杂志,2021,28(6):93-94.

相似文献/References:

[1]李向辉,卢文杰.葛黄降糖汤治疗2型糖尿病合并颈动脉硬化临床研究*[J].陕西中医,2019,(5):580.
　LI Xianghui,LU Wenjie..Effect of Gehuang Jiangtang decoction on mellitus complicated with carotid arteriosclerosis in type 2 diabetes patients[J].,2019,(8):580.
[2]杨斯皓,马方霞,詹 云.一贯煎合六味地黄汤配合西药治疗2型糖尿病合并非酒精性脂肪肝临床疗效及对患者生活质量的评价*[J].陕西中医,2019,(8):1006.
　YANG Sihao,MA Fangxia,ZHAN Yun..Clinical efficacy and quality of life evaluation of Yiguanjian plus Liuwei Dihuang decoction with western medicine in the treatment of type 2 diabetes with nonalcoholic fatty liver disease[J].,2019,(8):1006.
[3]孙晓红,陈学彬△.芪精丹兰汤对伴有左心室舒张功能不全的2型糖尿病合并代谢综合征患者糖脂代谢、心率变异性的影响*[J].陕西中医,2019,(10):1336.
　SUN Xiaohong,CHEN Xuebin..Effect of Qijing Danlan decoction on glucose and lipid metabolism and heart rate variability in patients with type 2 diabetes mellitus complicated with MS with left ventricular diastolic dysfunction[J].,2019,(8):1336.
[4]訾 璐,胡小军△,王 玉,等.针刺中脘穴联合自拟茶方对2型糖尿病患者血糖水平的影响*[J].陕西中医,2019,(10):1460.
　ZI Lu,HU Xiaojun,WANG Yu,et al.Effect of zhong wan acupuncture combined with selfdesigned tea prescription on blood glucose level in patients with type 2 diabetes mellitus[J].,2019,(8):1460.
[5]文启友,周 伶,马若梦,等.化瘀利尿法论治2型糖尿病探析[J].陕西中医,2021,(6):761.[doi:DOI:10.3969/j.issn.1000-7369.2020.06.021]
[6]谢兆桃,周卓宁,郑 鹏,等.从中焦论治2型糖尿病患者餐后血糖波动[J].陕西中医,2021,(6):764.[doi:DOI:10.3969/j.issn.1000-7369.2020.06.022]
[7]胡全穗,伍宗明.运用中药药对配伍优化消渴病中医防治方案临床研究[J].陕西中医,2021,(8):1084.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.024]
　HU Quansui,WU Zongming.Clinical research on optimizing the TCM prevention and treatment of Xiaoke by using compatibility of herb-partners[J].,2021,(8):1084.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.024]
[8]卢 昉,刘晓霞,梁佩玲,等.清热益气降糖方对2型糖尿病患者胰岛α、β细胞功能的影响[J].陕西中医,2021,(10):1400.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.019]
[9]刘厚利,呼兴华,何 莉,等.基于数据挖掘许建秦治疗湿热内蕴型糖尿病用药规律分析[J].陕西中医,2021,(10):1455.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.035]
[10]陈继玲,任珍珍,王劭敏,等.玉泉丸合生脉散联合二甲双胍治疗气阴两虚证2型糖尿病临床研究[J].陕西中医,2021,(11):1553.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.013]
　CHEN Jiling,REN Zhenzhen,WANG Shaomin,et al.Efficacy of Yuquan pills with Shengmai powder and metformin tablets in the treatment of T2DM with deficiency of Qi and Yin[J].,2021,(8):1553.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.013]

备注/Memo

备注/Memo:
基金项目:广东省中医药管理局科研项目(20182170); 广东省中山市社会公益科技研究项目(2019B1044)
更新日期/Last Update: 2022-08-10